Assignee
ALX ONCOLOGY INC
US·14 granted patents·19 pending applications·74 citations·filing 2016–2025
Top patents by PatentIndex Score
33 records- 0197US11208459B2Constructs having a SIRP-alpha domain or variant thereofALX ONCOLOGY INC·Filed 2020·Granted Dec 28, 2021·8 cites·54 claims
- 0296US10696730B2Constructs having a SIRP-alpha domain or variant thereofALX ONCOLOGY INC·Filed 2018·Granted Jun 30, 2020·11 cites·54 claims
- 0396US10259859B2Constructs having a SIRP-α domain or variant thereofALX ONCOLOGY INC·Filed 2016·Granted Apr 16, 2019·35 cites·137 claims
- 0494US11242404B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2021·Granted Feb 8, 2022·3 cites·30 claims
- 0593US11639376B2Constructs having a SIRP-α domain or variant thereofALX ONCOLOGY INC·Filed 2020·Granted May 2, 2023·3 cites·28 claims
- 0692US12098214B2Combination therapies for treating cancerALX ONCOLOGY INC·Filed 2022·Granted Sep 24, 2024·2 cites·6 claims
- 0792US11613564B2Methods of treating cancerALX ONCOLOGY INC·Filed 2020·Granted Mar 28, 2023·3 cites·7 claims
- 0891US11939393B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2022·Granted Mar 26, 2024·1 cites·24 claims
- 0991US11401338B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2017·Granted Aug 2, 2022·6 cites·37 claims
- 1086US2026001960A1Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 1185US2025011737A1Sirp-alpha variant constructs and uses thereofALX ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 1285US2024343778A1Constructs having a sirp-alpha domain or variant thereofALX ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1384US11292850B2Antibodies against signal-regulatory protein α and methods of useALX ONCOLOGY INC·Filed 2019·Granted Apr 5, 2022·2 cites·62 claims
- 1482US2024228574A9Methods of treating cancerALX ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1581US2023340433A1Sirp-alpha variant constructs and uses thereofALX ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1678US12527838B2Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancelALX ONCOLOGY INC·Filed 2023·Granted Jan 20, 2026·0 cites·13 claims
- 1777US2025368712A1Methods of treating cancerALX ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 1876US2022242928A1Methods of treating cancerALX ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1975US12404340B2Antibodies against signal-regulatory protein alpha and methods of useALX ONCOLOGY INC·Filed 2021·Granted Sep 2, 2025·0 cites·37 claims
- 2075US2024075101A1Combination therapies for treating cancerALX ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2175US2020263154A1Sirp-alpha variant constructs and uses thereofALX ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 2275US2024327527A1Activatable antibodies and methods of use thereofALX ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 2375US2022213166A1Methods of treating cancerALX ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 2474US2021388329A1Sirp-alpha variant constructs and uses thereofALX ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 2569US2018371435A1Sirp-alpha variant constructs and uses thereofALX ONCOLOGY INC·Filed 2018·Application pending·0 cites
- 2664US2021154269A1Combination therapies for treating cancerALX ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2762US2024010701A1Combination therapies for treating urothelial carcinomaALX ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2858US11939385B2Activatable antibodies and methods of use thereofALX ONCOLOGY INC·Filed 2018·Granted Mar 26, 2024·0 cites·9 claims
- 2958US2025101032A1Exatecan derivatives and antibody-drug conjugates thereofALX ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 3056US2022196651A1Multimers for reducing the interference of drugs that bind cd47 in serological assaysALX ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 3154US12343377B2Combination therapies comprising a hypomethylation agent for treating cancerALX ONCOLOGY INC·Filed 2021·Granted Jul 1, 2025·0 cites·17 claims
- 3253US2021347848A1Decoy polypeptidesALX ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 3349US2020400662A1Methods and reagents for reducing the interference of drugs that bind cd47 in serological assaysALX ONCOLOGY INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ALX ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →